Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are at least 18 years old
- People who are able to understand and willing to sign a consent form (a legal representative may sign on their behalf if needed)
- People who have been diagnosed with a specific type of multiple myeloma (called IgG or IgA multiple myeloma) and have received a stem cell transplant using their own cells (called an autologous transplant) as part of their first course of treatment
- People whose first course of treatment included at least three cancer medicines, including specific drug types known as a PI and an IMID, with or without an anti-CD38 antibody medicine
- People whose myeloma has responded at least partially to treatment, based on standard measurement criteria, at the time of joining the study
- People whose myeloma is still detectable at a low level (called MRD-positive) on a specialised bone marrow test done around 100 days after their stem cell transplant
- People who are generally well enough to carry out light activity and care for themselves (assessed using a standard health scale)
- People whose side effects from previous treatment have mostly resolved to a mild level before joining
- People whose blood counts and organ function (bone marrow, liver, and kidneys) meet specific minimum levels within 28 days before starting treatment
- People of childbearing potential and male participants who agree to use reliable contraception during the study and for 5 months after treatment ends
Who may not be able to join:
- People whose myeloma cells cannot be tracked using the specific laboratory test (clonoSEQ) required by this trial
- People who have had another type of cancer, with some exceptions: non-melanoma skin cancers, certain low-risk prostate cancers, and cancers for which all treatment was completed at least 2 years ago with no signs of disease remaining (hormone therapy for breast cancer is also not disqualifying)
- People who are currently taking part in another clinical trial involving an experimental treatment
- People who have previously received a treatment that targets a protein called BCMA
- People whose myeloma has spread to the brain or spinal cord
- People who have had a serious allergic reaction to medicines similar to the study drug (elranatamab)
- People with certain serious or uncontrolled conditions, including plasma cell leukemia, POEMS syndrome, systemic amyloidosis, or an active ongoing infection
- People who are pregnant or breastfeeding; women of childbearing potential must have a negative pregnancy blood test within 28 days before starting the study drug
- People living with HIV who are not on effective HIV treatment or who have not had an undetectable level of virus in their blood for at least the past 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Slade, M.D., Washington University School of Medicine
Phone: 314-454-8304
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS); Proportion of patients achieving MRD negativity at the 10^-5 threshold per the clonoSEQ assay
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.